ENAH: A Potential Drug Target for Pain Therapies (G55740)

Target Name: ENAH

NCBI ID: G55740

ENAH

ENAH: A Potential Drug Target for Pain Therapies

ENAH, or mammalian enabled variant 11a, is a protein that is expressed in the brain and other nervous tissue in mammals. It is a member of the neurotrophic factor receptor family, which is a group of transmembrane proteins that are involved in the regulation of neural stem cells and their differentiation.

ENAH has been shown to play a role in the development and maintenance of neural stem cells, as well as their ability to differentiate into various cell types within the nervous system. This is important for the development and treatment of neural injuries, such as those caused by trauma or disease.

In addition to its role in neural stem cell biology, ENAH has also been shown to play a role in the regulation of pain perception and the modulation of neurotransmitter release in the brain. This makes it an attractive drug target for the development of pain therapies.

ENAH has been shown to interact with several different neurotransmitters, including GABA, glutamate, and neurotensin. These interactions are important for the regulation of neural activity and the modulation of pain perception.

One of the key challenges in the study of ENAH is its expression and function in the brain, as the brain is a complex and dynamic system. However, research into ENAH has provided valuable insights into the regulation of neural stem cells and the development of neural injuries.

ENAH has been shown to play a role in the regulation of neural stem cell proliferation and differentiation. This is important for the development of neural injuries, as neural stem cells are the source of new neurons that are involved in the repair and regeneration of damaged tissue.

In addition to its role in neural stem cell biology, ENAH has also been shown to play a role in the regulation of pain perception and the modulation of neurotransmitter release in the brain. This makes it an attractive drug target for the development of pain therapies.

ENAH has been shown to interact with several different neurotransmitters, including GABA, glutamate, and neurotensin. These interactions are important for the regulation of neural activity and the modulation of pain perception.

One of the key challenges in the study of ENAH is its expression and function in the brain, as the brain is a complex and dynamic system. However, research into ENAH has provided valuable insights into the regulation of neural stem cells and the development of neural injuries.

ENAH has been shown to play a role in the regulation of neural stem cell proliferation and differentiation. This is important for the development of neural injuries, as neural stem cells are the source of new neurons that are involved in the repair and regeneration of damaged tissue.

In addition to its role in neural stem cell biology, ENAH has also been shown to play a role in the regulation of pain perception and the modulation of neurotransmitter release in the brain. This makes it an attractive drug target for the development of pain therapies.

Overall, ENAH is a protein that has important roles in the regulation of neural stem cell biology and pain perception. As such, it is a potential drug target for the development of pain therapies. Further research is needed to fully understand the function and regulation of ENAH in the brain, and to develop effective treatments for neural injuries and pain.

Protein Name: ENAH Actin Regulator

Functions: Ena/VASP proteins are actin-associated proteins involved in a range of processes dependent on cytoskeleton remodeling and cell polarity such as axon guidance and lamellipodial and filopodial dynamics in migrating cells. ENAH induces the formation of F-actin rich outgrowths in fibroblasts. Acts synergistically with BAIAP2-alpha and downstream of NTN1 to promote filipodia formation (By similarity)

The "ENAH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENAH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets